Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period.
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs S 18986 (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 05 Apr 2017 Status changed from suspended to discontinued.
- 15 Nov 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 15 Nov 2010 Planned end date changed to 1 May 2006 as reported by ClinicalTrials.gov.